[HTML][HTML] Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

H Tan, T Yue, Z Chen, W Wu, S Xu… - International Journal of …, 2023 - ncbi.nlm.nih.gov
Cardiovascular and metabolic disease (CVMD) is becoming increasingly prevalent in
developed and developing countries with high morbidity and mortality. In recent years …

The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues

E Li, MAG van der Heyden - Naunyn-Schmiedeberg's Archives of …, 2024 - Springer
The functioning of the human heart relies on complex electrical and communication systems
that coordinate cardiac contractions and sustain rhythmicity. One of the key players …

Mechanism of fibroblast growth factor 21 in cardiac remodeling

Z Zhao, X Cui, Z Liao - Frontiers in Cardiovascular Medicine, 2023 - frontiersin.org
Cardiac remodeling is a basic pathological process that enables the progression of multiple
cardiac diseases to heart failure. Fibroblast growth factor 21 is considered a regulator in …

Examining genetic and epigenetic regulation in cardiovascular development, regeneration and disease

E Abdelwahid… - Frontiers in …, 2023 - frontiersin.org
Heart disease is the leading cause of death worldwide and is associated with significant
socioeconomic problems. Examining genetic and epigenetic regulation in cardiovascular …

[HTML][HTML] CPAL, as a new mediator of cardiomyocyte metabolic alterations and Pyroptosis, regulates myocardial infarction injury in mice

J Li, H Xue, N Xu, L Gong, M Li, S Li, D Huang… - Engineering, 2023 - Elsevier
Myocardial infarction (MI), the most serious of the ischemic heart diseases, is accompanied
by myocardial metabolic disorders and the loss of cardiomyocytes. Increasing evidence has …

[HTML][HTML] Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases

AM Alieva, IE Baikova, EV Reznik, RK Valiev… - Medical Journal of the …, 2022 - medjrf.com
Currently, the search and study of new biological markers that can assist in the early
diagnosis of cardiovascular diseases, serving as a laboratory tool for assessing the …

[PDF][PDF] Фактор роста фибробластов 21-новый инструмент в многокомпонентной оценке сердечно-сосудистых заболеваний

АМ Алиева, ИЕ Байкова, ЕВ Резник… - Российский …, 2022 - medjrf.com
АННОТАЦИЯ В современном мире остается актуальным поиск и изучение новых
биологических маркеров, способных помогать ранней диагностике сердечно …

Prospects for the Use of Cell Cultures in Modeling Myocardial Diseases: Hypertrophic Cardiomyopathy

AL Klass, MI Shadrina, PA Slominsky… - Cell and Tissue Biology, 2024 - Springer
The use of various model organisms has made a huge contribution to understanding the
causes and mechanisms of disease development and the study of pathological processes …

Inhibitory Effects of Nobiletin on Voltage-Gated Na+ Channel in Rat Ventricular Myocytes Based on Electrophysiological Analysis and Molecular Docking Method

Y Gu, J Wang, M Li, F Zhong, J Xiang, Z Xu - International Journal of …, 2022 - mdpi.com
Nobiletin (NOB) has attracted much attention owing to its outstanding bioactivities. This
study aimed to investigate its anti-arrhythmic effect through electrophysiological and …

Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation

Q Zhang, W Zhao, Z Sun, X Dong, L Zhu… - Frigid Zone …, 2024 - degruyter.com
Background Nonalcoholic fatty liver disease (NAFLD) is a chronic condition characterized by
a progressive decline in liver function, leading to disruptions in liver integrity and metabolic …